Smart blood test guides treatment for stubborn hodgkin lymphoma

NCT ID NCT07021989

Not yet recruiting Disease control Sponsor: Michael Spinner, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times

Summary

This study tests a combination of the immunotherapy drug pembrolizumab and three chemotherapy drugs (GVD) in 38 adults whose Hodgkin lymphoma returned or did not respond to one prior treatment. A special blood test (ctDNA) is used to see how well the treatment is working and to guide next steps. The goal is to achieve a complete response, meaning no cancer is detectable by both the blood test and PET scan.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLASSIC HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma Hodgkins lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLASSIC HODGKIN LYMPHOMA HODGKIN LYMPHOMA, ADULT REFRACTORY HODGKIN LYMPHOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

University of California Davis

Davis, California, 95616, United States
University of California Irvine

Irvine, California, 92617, United States
University of California San Francisco-Fresno

Fresno, California, 93701, United States
University of California, San Diego

La Jolla, California, 92093, United States
University of California, San Francisco

San Francisco, California, 94143, United States

Contact Email: •••••@•••••
Unversity of California, Los Angeles

Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.